A unique approach to bring open innovation to EuropeIn February, Johnson & Johnson Innovation, JLABS opened its first European open innovation incubator, JLABs @ BE, at the heart of the Beerse Janssen R&D Campus in Belgium. European Biotechnology … more ➔
Diversifying into oncology if ROI on bugs is too lowBig Pharma’s interest in R&D on anti-infectives declined when other areas like oncology began offering higher returns. A few biotechs mirror pharma (Basilea, Idorsia and Polyphor), but could stay … more ➔
Formulation mattersBack in February 2017, CDMO Rentschler Biopharma SE and formulation specialist Leukocare AG joined forces to give biologics and biosimilar makers a competitive edge through significantly stabilised end … more ➔
Turning cancer into a chronic diseaseFollowing last year’s approval by the US FDA, the EU’s EMA has now also approved the first two T-cell-based immunotherapies against certain types of cancer. This marks the ultimate proof-of-concept … more ➔
Skilful asset swapping in the time of big dataIndependent investment analyst, Managing Director EQUI.TS GmbH_ Big data analytics is poised to change the way business is done in the life sciences. A string of recent M&A transactions illustrate … more ➔
Single-use plastics: New EU rules to reduce marine litter Plastics are magical materials, and they will be even more important in the future than they are today. But they lead to microplastics in the environment, especially noticeable as marine littering. … more ➔
Balancing generic and innovative medical usesIs cheaper always better when it comes to generics? What about when it comes to innovative medical uses of them? more ➔
Merging industriesIn mid-November, the European Commission tabled the long-awaited review of its Bioeconomy Strategy and Action Plan. European Biotechnology spoke with Waldemar Kütt, Head of Unit Bioeconomy Strategy, … more ➔
